Find Linperlisib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1702816-75-8, Pi3kdelta-in-2, Pi3k(delta)-in-2, 05hyk3cv9n, Yy-20394, Pi3k
Molecular Formula
C28H37FN6O5S
Molecular Weight
588.7  g/mol
InChI Key
NVWKNQGHVMMAJW-UHFFFAOYSA-N
FDA UNII
05HYK3CV9N

Linperlisib
Linperlisib is an orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration linperlisib selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.
1 2D Structure

Linperlisib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[5-[6-fluoro-8-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-2-morpholin-4-ylquinazolin-4-yl]-2-methoxypyridin-3-yl]methanesulfonamide
2.1.2 InChI
InChI=1S/C28H37FN6O5S/c1-28(2,36)20-5-7-34(8-6-20)17-19-13-21(29)15-22-24(31-27(32-25(19)22)35-9-11-40-12-10-35)18-14-23(33-41(4,37)38)26(39-3)30-16-18/h13-16,20,33,36H,5-12,17H2,1-4H3
2.1.3 InChI Key
NVWKNQGHVMMAJW-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(C1CCN(CC1)CC2=C3C(=CC(=C2)F)C(=NC(=N3)N4CCOCC4)C5=CC(=C(N=C5)OC)NS(=O)(=O)C)O
2.2 Other Identifiers
2.2.1 UNII
05HYK3CV9N
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1702816-75-8

2. Pi3kdelta-in-2

3. Pi3k(delta)-in-2

4. 05hyk3cv9n

5. Yy-20394

6. Pi3k

7. A-in-2

8. N-[5-[6-fluoro-8-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-2-morpholin-4-ylquinazolin-4-yl]-2-methoxypyridin-3-yl]methanesulfonamide

9. Methanesulfonamide, N-(5-(6-fluoro-8-((4-(1-hydroxy-1-methylethyl)-1-piperidinyl)methyl)-2-(4-morpholinyl)-4-quinazolinyl)-2-methoxy-3-pyridinyl)-

10. N-(5-(6-fluoro-8-((4-(2-hydroxypropan-2-yl) Piperidin-1-yl)methyl)-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-)methanesulfonamide

11. Linperlisib [inn]

12. Pi3kd-in-2

13. Pi3ko-in-2

14. Unii-05hyk3cv9n

15. Pi3k.delta.-in-2

16. Linperlisib [who-dd]

17. Pi3k -in-2

18. Chembl4574601

19. Schembl18032489

20. Gtpl10466

21. Us9656996, Compound 10

22. Bdbm309960

23. Bcp20830

24. Ctc81675

25. Ex-a1436

26. Pi3k(c)(1/2)-in-2

27. Cs-6973

28. Yy20394

29. Compound 10 [us20160244432]

30. Yy-20394; Pi3k

31. A-in-2

32. Ac-35638

33. Hy-102031

34. N-[5-[6-fluoro-8-[[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]methyl]-2-(4-morpholinyl)-4-quinazolinyl]-2-methoxy-3-pyridinyl]-methanesulfonamide

2.4 Create Date
2015-05-04
3 Chemical and Physical Properties
Molecular Weight 588.7 g/mol
Molecular Formula C28H37FN6O5S
XLogP32.1
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count12
Rotatable Bond Count8
Exact Mass588.25301764 g/mol
Monoisotopic Mass588.25301764 g/mol
Topological Polar Surface Area138 Ų
Heavy Atom Count41
Formal Charge0
Complexity958
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 1702816-75-8 / Linperlisib API manufacturers, exporters & distributors?

Linperlisib manufacturers, exporters & distributors 1

22

PharmaCompass offers a list of Linperlisib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Linperlisib manufacturer or Linperlisib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Linperlisib manufacturer or Linperlisib supplier.

PharmaCompass also assists you with knowing the Linperlisib API Price utilized in the formulation of products. Linperlisib API Price is not always fixed or binding as the Linperlisib Price is obtained through a variety of data sources. The Linperlisib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Linperlisib

Synonyms

1702816-75-8, Pi3kdelta-in-2, Pi3k(delta)-in-2, 05hyk3cv9n, Yy-20394, Pi3k

Cas Number

1702816-75-8

Unique Ingredient Identifier (UNII)

05HYK3CV9N

About Linperlisib

Linperlisib is an orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration linperlisib selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.

Linperlisib Manufacturers

A Linperlisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Linperlisib, including repackagers and relabelers. The FDA regulates Linperlisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Linperlisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Linperlisib Suppliers

A Linperlisib supplier is an individual or a company that provides Linperlisib active pharmaceutical ingredient (API) or Linperlisib finished formulations upon request. The Linperlisib suppliers may include Linperlisib API manufacturers, exporters, distributors and traders.

Linperlisib GMP

Linperlisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Linperlisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Linperlisib GMP manufacturer or Linperlisib GMP API supplier for your needs.

Linperlisib CoA

A Linperlisib CoA (Certificate of Analysis) is a formal document that attests to Linperlisib's compliance with Linperlisib specifications and serves as a tool for batch-level quality control.

Linperlisib CoA mostly includes findings from lab analyses of a specific batch. For each Linperlisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Linperlisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Linperlisib EP), Linperlisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Linperlisib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty